Multiple Antibiotics, 4 Cancer Drugs More Affordable As Government Adds 34 Drugs To Essential Medicines List – Bollyinside

0

Several antibiotics, vaccines, cancer drugs and many other important drugs will become more affordable, reducing patient expenses. NLEM drugs fall under the intended category and their price is regulated by the National Pharmaceutical Pricing Authority. Speaking on the occasion, Mandaviya said his ministry is taking various steps in line with Prime Minister Narendra Modi’s vision of Sabko Dawai, Sasti Dawai.

Several cancer drugs, antibiotics and vaccines will now become more affordable as they are among 34 new additions to the national essential medicines list, and the government says this will reduce out-of-pocket expenses for patients.

Anti-infective drugs such as ivermectin, mupirocin and meropenem were added to the list, bringing the total number of drugs to 384.

Four main anticancer drugs have been added to the list – bendamustine hydrochloride, irinotecan hydrochloride trihydrate, lenalidomide and leuprolide acetate, which are effective in various types of cancer – and psychotherapeutic drugs – replacement therapy nicotine and buprenorphine.

However, 26 drugs such as ranitidine, sucralfate, white petrolatum, atenolol and methyldopa were removed from the previous list of 376 drugs. The deletion was made based on cost-effectiveness parameters and the availability of better drugs. NLEM withdrawal criteria include – banned in India, reports of safety profile concerns, disease burden for which the drug is indicated is no longer a national health concern and, for antimicrobials, whether the model of resistance made it ineffective.

Following the release of the list on Tuesday, EU Health Minister Mansukh Mandaviya tweeted: “He released the National Essential Medicines List 2022. It includes 384 medicines in 27 categories. Several antibiotics, vaccines, cancer drugs and many other important drugs will become more affordable and reduce patient expenses. “NLEM drugs fall under the intended category and their price is regulated by the National Pharmaceutical Pricing Authority.

Speaking on the occasion, Mandaviya said his ministry is taking various steps in line with Prime Minister Narendra Modi’s vision towards “Sabko Dawai, Sasti Dawai”. “In this direction, the National List of Essential Medicines (NLEM) plays an important role in ensuring the availability of affordable and high-quality medicines at all levels of health care. This will ensure an increase in cost-effective, high-quality medicines and help reduce over-the-counter healthcare expenditures for citizens,” he said.

The main goal of NLEM is to promote the rational use of medicines by considering three important aspects – cost, safety and effectiveness, Mandaviya said.

That said, the NLEM is a living document and is regularly updated taking into account changing public health priorities as well as advances in pharmaceutical science. The NLEM was formulated in 1996 and has been updated three times previously in 2003, 2011 and 2015.

The revision of NLEM 2022 was made after continuous consultation with stakeholders from academia, industry and public policy experts, etc. and key documents such as the WHO EML 2021.

Endocrine and contraceptive drugs were added to the amended list: fludrocortisone, ormeloxifene, insulin glargine and teneliglitine.

Montelukast, which acts on the airways, and the eye medication Latanoprost are also on the list. In addition to drugs used in palliative care, the list also includes the cardiovascular drugs Dabigatran and Tenecteplaza.

“Anti-infectives such as ivermectin, meropenem, cefuroxime, amikacin, bedaquiline, delamanid, itraconazole ABC Dolutegravir have been added to the NLM,” said Dr. YK Gupta, vice president of the Standing National Drugs Committee. A rotavirus vaccine has also been added to the list.

The drugs in the NLEM fall into the intended category and their price is regulated by the National Pharmaceutical Pricing Authority, Dr Gupta said.

Covid drugs and vaccines weren’t added to the list, he said, because they got emergency approvals, and the data is still not conclusive and complete from a regulatory standpoint.

The committee discussed the need for drugs for COVID-19. Conditional/emergency approval has been granted to some new drugs for COVID-19 given the risk of pandemic accumulation versus potential benefit (risk-benefit ratio) based on available in vitro studies, non-clinical and clinical data, concluded Dr. Gupta.

“The Committee also places great importance on the rational use of antimicrobials by all stakeholders, including manufacturers, physicians, patients and veterinary experts,” he said.

A revised list of 399 preparations was submitted by an expert committee within the Indian Council for Medical Research (ICMR) last year. After a detailed analysis of Indian requirements, Mandaviya sought significant changes.

The criteria for inclusion of drugs in the NLEM are as follows: they are useful in diseases of public health concern in India, licensed/approved by the General Drug Controller of India (DCGI), have an efficacy profile and proven evidence-based safety, are relatively cost-effective and must adhere to current and recommended treatment guidelines under India’s national health programs. (e.g. ivermectin under the 2018 Accelerated Lymphatic Filariasis Elimination Plan). PTI PLB ZMN

(This story has not been edited by our team of editors and was generated from the stream.)

Share.

About Author

Comments are closed.